COMPUMEDICS®

'Defining *Life's* Signals'

CORPORATE HIGHLIGHTS 2025



- Sleep Diagnostics & Treatment
- Neuro Diagnostics
- Brain Research
- Ultrasonic Blood Flow Monitoring
- Medical Innovations

COMPUMEDICS®

FY 25 Performance Highlights

- **Record sales orders:** $63.4m (+22%)
- **Revenue:** $51m (↑15% ex-MEG)
- **EBITDA:** $2.9m (+9%)
- **Gross margins:** 55%

- **FY26 Outlook:** Revenue > $70m, EBITDA ~ $9m
- Record year of execution, sales, growth, sales pipeline & transformation to AI Sleep platform-based Medtech

Key Performance Measures

✓ SOMFIT® SALES LEADERSHIP TEAMS IN PLACE IN USA (SaaS)	✓ SOMFIT® D FDA CLEARANCE	✓ TJNU MEG SUCCESSFULLY INSTALLED
SaaS® REVENUES ▲ $6.7M UP FROM $4.5M in FY24	USA REVENUES ▲ $17.7M UP FROM $10.5M in FY24	3 MEG OPEN ORDERS ▲ 15.0M SECURED SET FOR INSTALLATION IN FY26
RECORD ORDERS TAKEN ▲ $63.4M UP FROM $52.0M IN FY24	RECORD REVENUE ▲ $51.0M UP FROM $49.7M IN FY24	EBITDA ▲ $2.9M UP FROM $2.7M IN FY24

Breakout Growth Platforms

- **Somfit® SaaS** – $6.7m (+49%), FDA cleared, >700k studies, $10m+ U.S. pipeline; Philips Pharmacy Strategic Partnership; Resmed Major Client; Major Deals: Big Pharmaceutical Co's & related Contract Research Organisations.
- **OrionMEG®** – 3 systems in FY26 (~$15m revenue), $20m sales in start-up phase (China alone) U.S. entry underway; Independent UCSD validation confirming global leadership status.
- **Nexus 360® SaaS** – >800k studies, expanded enterprise workflows.
- **Neuroscan®/OKTI®** – Revenue doubled, CURRY® sales +15%.
- **DWL®** – FDA/EU MDR approved EZ-Dop®, AI Robotic TCD in development.
- **Alpha Trace®** – €1m sales, Kepler Clinics contract.

Compumedics Somfit® FY25 Highlights - At a Glance

$6.7M
Somfit© & SaaS revenue (up from $4.2m in FY24)

11%
Of total company revenue

$20M+
Pipeline post U.S. launch & FDA approval

Expansion into Pharma
- $2m initial orders from two global pharma companies
- Further trials expected FY28

Strategic Deals
- $3m PA Philips
- Top Tier U.S. IDTFs
- Global leading Somfit© SaaS Pharma CRO and big Pharma

Regulatory Milestones
- Approvals: Brazil, Colombia, Hong Kong, Singapore
- U.S. Somfit© Pro U.S. FDA in process for early '26FY

Scientific Validation
- 3 peer-reviewed publications
- More in progress to strengthen adoption

Broader Business Progress
- Total over 770,000 Somfit© and NEXUS360© SaaS studies
- Somfit SaaS secures 75% AU HST pharmacy market

Positioned for FY26 Growth
- Somfit© expansion, product launches and new market entry

Market Upside Opportunities

- **OrionMEG®:** ~$13.6B (10% MRI-equivalent adoption)- Renewed CMP Board to Access Mkt.
- **Somfit® SaaS:**
  - USA reimbursement market ~$250m – growth 25% PA - CMP fastest growing AI Sleep (HST/SaaS).
- **Global reimbursement** ~$1B.
- **Consumer potential $1–10B** (Apple/Google/Amazon partnerships)- Renewed CMP Board to Access Mkt.

Compumedics OrionMEG® LifeSpan FY25 Highlights - At a Glance

$20M

'25: Four Compumedics MEG labs for total of about $20m in revenues, in China alone

U.S. Market Launch in '26

USA as the world's largest MEG market, will now bolster CMP MEG progress in China, the world's fastest growing market

Validation

"Leading-edge OrionMEG© LifeSpan dual whole-head MEG system from Compumedics is truly a state-of-the-art MEG system."

'25: Prof. Mingxiong Huang UCSD Dep. Rad.& Dep. Elect. & Comp. Eng., Co-Direct. MEG Centre, Scientist & Physicist VA San Diego (ASX: CMP: 30 Sep25)

Innovation Edge

World-first OrionMEG© LifeSpan:
- Unique dual-helmet child/adult
- Virtual 100% coolant recycling 24/7 operation
- CURRY MEG s/w years ahead of competitors
- Total non-invasive technique

Positioned for FY26 Growth

Plan to launch latest OrionMEG© LifeSpan USA, China

Board Strengthened

NED MEG Major Strategic Deal Laser Focus

Manufacturing Growth

Factory expansion and MSR installed

Why Invest Now

- **Large, under-penetrated global markets** (sleep & neuro diagnostics).
- **Scalable SaaS** recurring revenues.
- **FDA/CE approvals** reduce execution risk.
- **Strategic Board renewal** with U.S. MedTech leadership onboard- Accelerate Strategic Partner Engagement & Market Access.
- CMP ~1x revenues vs peers at 4–8x – substantial investor intrinsic value- realisation.

Valuation Gap



Compumedics' Valuation Gap



CMP Takeaway Message for Shareholders

Compumedics is at an **inflection point** - scaling FDA-cleared platforms (Somfit®), commercializing world-class neuroimaging (OrionMEG®), and building recurring SaaS revenues. Combined with strong FY25 execution and a Board focused on capital markets, CMP is poised to unlock both **operational growth** and a **capital market re-rating**.

Q&A Responses – CFO & CEO, Compumedics (CMP)

1. Performance & FY25 Results

Q: ***What drove Compumedics' record performance in FY25?***

A: "FY25 was a year of disciplined execution. We grew sales orders by 22% to a record $63.4 million, while expanding gross margins to 55% through stronger product mix and in-house manufacturing efficiencies. Importantly, we advanced our growth platforms - Somfit® and OrionMEG® - while maintaining profitability at the core. This balance of innovation and operational discipline sets us apart."

2. Somfit® Opportunity

Q: ***Why is Somfit® such a pivotal growth engine for CMP?***

A: "Somfit® addresses one of the largest unmet needs in healthcare: scalable, at-home sleep diagnostics. With FDA clearance in the U.S., we're already seeing strong adoption. Revenue from Somfit® and SaaS reached $6.7 million, up 49% year-on-year, and we've secured partnerships with Philips, major CPAP providers including Resmed, and pharmaceutical companies. This isn't just a product - it's a recurring SaaS revenue model in a market expected to grow at 12% annually."

Q: ***Why did revenue grow only 2% while orders grew 22%?***

A: Timing of OrionMEG® deliveries (FY26 recognition) affected revenue. Underlying revenue growth ex-MEG was 15%.

3. SaaS Value Creation

Q: ***How does the SaaS component change CMP's business model?***

A: "Traditionally, medtech has been transaction-based. SaaS transforms our business into one with predictable, recurring revenues. Over 800,000 studies have already been completed on our NEXUS 360® and Somfit® platforms, and every study adds long-term stickiness and margin. Investors should view this as a shift toward a high-quality, compounding revenue base."

Q: ***How big is the opportunity for Somfit® SaaS?***

A: The U.S. HST SaaS market is ~$250m, global >$1B, with consumer opportunity $1–10B. Somfit® already has FDA clearance, >70k studies, and a $10m+ pipeline.

4. OrionMEG® Expansion

Q: ***What does OrionMEG® bring to CMP's growth story?***

A: "OrionMEG® is Compumedics' breakthrough in brain functional imaging. We've secured orders worth about $15 million for FY26 ($20m in sales start-up phase in China alone) and had independent validation from UCSD confirming it as among the best MEG systems in the world. With the U.S. market now in focus, OrionMEG® has the potential to be a globally transformative platform, complementing our leadership in sleep diagnostics."

Q: ***How does OrionMEG® compare with MRI?***

A: OrionMEG® is validated as a world-leading functional brain imaging platform; i.e greater temporal resolution and hence most suited to enormous health burden neuro-functional disorders such as epilepsy, autism, Alzheimer's, Parkinsons, traumatic brain injury, and mental disorders. With potential adoption akin to MRI's growth curve, the market upside is ~$13.6B.

5. Capital Market Valuation

Q: ***Why do you believe CMP is undervalued by the market?***

A: "Despite record orders and revenue, CMP trades at around 1× revenues. Comparable medtech peers trade at 4–8×, with health AI SaaS peers much higher. Even applying conservative multiples, our implied valuation should be three to five times higher. We're addressing this by refreshing our Board with directors experienced in U.S. MedTech and capital markets, improving investor communication, and delivering milestones that highlight our true scale."

6. Innovation & Differentiation

Q: ***How is CMP differentiated from competitors?***

A: "Our strength lies in clinical credibility and innovation. Somfit® is the only device combining brain and respiratory measures for true sleep assessment. Our AI algorithms match expert clinicians in scoring accuracy, validated in peer-reviewed publications. OrionMEG® delivers dual-helmet brain imaging unmatched globally. And critically, we have the regulatory foundation—FDA, CE, Asia-Pacific—that many emerging players lack."

7. Outlook for FY26

Q: ***What should investors expect in FY26?***

A: "We're guiding revenue above $70 million and EBITDA of about $9 million. The growth will be driven by Somfit's U.S. expansion, OrionMEG® deliveries, and SaaS scaling. Operational leverage from in-house manufacturing and supplier resets will further lift margins. FY26 is about building on momentum, accelerating global adoption, and unlocking shareholder value."

Q: ***What impact will Board renewal have on valuation?***

A: The appointment of Christopher R. Barys brings U.S. MedTech and capital markets expertise. Board renewal directly addresses undervaluation strategic trade and investment partnership opportunities (CMP ~1x revenue vs peers at 4–8x).

Q: ***Why invest in Compumedics now?***

A: CMP combines FDA-cleared technologies, SaaS recurring revenues, U.S. expansion, board renewal, and trades well below peer valuation multiples – creating for first of its kind re-rating opportunity with proven high-impact commercialisation, scaleability evidence for Somfit's and OrionMEG,® whilst delivering record core business outcomes.

8. Investor Takeaway

Q: ***What's the single message you want investors to remember?***

A: "Compumedics is at an inflection point. We have validated technologies, global regulatory approvals, and rapidly scaling platforms in multi-billion-dollar markets. With SaaS recurring revenues, OrionMEG® expansion, and Board renewal to unlock capital market value, we are positioned not just for growth—but for a re-rating that will close the gap between our performance and our share price." (CMP AR '25 SNAPSHOT)

Disclaimers

This presentation (the "Presentation") has been prepared by Greenhill & Co. Australia Pty Limited, its partners and affiliates (collectively, "Greenhill") exclusively for the benefit and internal use of the recipient ("you" or the "Recipient") solely for its use in evaluating the transaction described herein and may not be used for any other purpose or copied, distributed, reproduced, disclosed or otherwise made available to any other person without Greenhill's prior written consent. This Presentation may only be relied upon by the Recipient and no other person. Greenhill is acting solely for the Recipient in connection with any arrangements, services or transactions referred to in this document. Greenhill is not and will not be responsible to anyone other than the Recipient for providing the protections afforded to the clients of Greenhill or for providing advice in relation to the arrangements, services or transactions referred to in this Presentation.

This Presentation is delivered subject to the terms of the engagement letter entered into between the Recipient and Greenhill. This document is delivered as at the date specified on the cover; Greenhill does not have any obligation to provide any update to or correct any inaccuracies in the information in this document.

This Presentation does not constitute an opinion, and is not intended to be and does not constitute a recommendation to the Recipient as to whether to approve or undertake or take any other action in respect of any transactions contemplated in this Presentation. The commercial merits or suitability or expected profitability or benefit of such transactions should be independently determined by the Recipient based on its own assessment of the legal, tax, accounting, regulatory, financial, credit and other related aspects of the transaction, relying on such information and advice from the Recipient's own professional advisors and such other experts as it deems relevant. Greenhill does not provide accounting, tax, legal or regulatory advice.

Confidentiality

This Presentation may not be used for any other purpose or copied, distributed, reproduced, disclosed or otherwise made available to any other person without Greenhill's prior written consent. By accepting this Presentation, you acknowledge and agree: (i) with all of the following terms and conditions; (ii) you are an authorized recipient of this Presentation who is permitted to receive this Presentation under applicable laws and regulations; (iii) you will keep all of the information contained herein strictly confidential; and (iv) you will, and will cause your parent(s), subsidiaries and affiliates and your and their respective directors, partners, officers, employees, advisors and representatives to use the information in the Presentation only to evaluate your potential interest in Greenhill's services as described herein and you, and they, will not divulge any of such information to any other party, except as otherwise required by law or regulation. Any retransmission or reproduction of the information in the Presentation, in whole or in part, in any format is strictly prohibited, unless otherwise required by law or regulation.

No Representations

These materials contain preliminary information that is subject to change and that is not intended to be complete or to constitute all the information necessary to adequately evaluate the consequences of any potential transaction. Greenhill makes no representation or warranty (express or implied) with respect to the information contained herein. Greenhill has no duty or obligation to update or revise the information contained in these materials. In preparing this document, Greenhill has relied on publicly available information and other information, including, if applicable, financial estimates, projections and forecasts provided to it by the Recipient, the relevant counterparty and their respective representatives and/or advisers and has assumed, without independent verification, the accuracy and completeness of all such information. None of Greenhill nor any member of its group or their respective partners, directors or employees accept any responsibility or liability (express or implied) whatsoever for any loss arising, directly or indirectly, from use of or reliance on, this document or any other written or oral communications with or information provided to the Recipient in connection with its subject matter. Greenhill has not conducted any evaluation or appraisal of any assets or liabilities of the company or companies mentioned herein or of any other person referred to in this document. Although all information has been obtained from and is based on sources believed to be reliable, no undertaking, representation or warranty, express or implied, is made by Greenhill in relation to the accuracy or completeness of the information presented herein or any other written or oral communications with or information provided, or its suitability for any particular purpose.

Forward Looking Statements/Past Performance

Certain information included herein, such as financial analysis, estimates, projections and forecasts may contain "forward-looking" information that is not purely historical in nature, and which involve risk and uncertainty, such as business, economic and regulatory changes, which could cause actual results to differ materially from such estimates, projections and forecasts. Any forward-looking information contained herein is based upon certain assumptions about future events or conditions and is intended only to illustrate hypothetical results under those assumptions (not all of which will be specified herein). Not all relevant events or conditions may have been considered in developing such assumptions. The success or achievement of various results and objectives is dependent upon a multitude of factors, many of which are beyond the control of Greenhill. No representations are made as to the accuracy of such estimates or projections or that such projections will be realized. Actual events or conditions are unlikely to be consistent with, and may differ materially from, those assumed. Due to various risks and uncertainties, actual events or results may differ materially from those reflected or contemplated in such forward looking statements.

Potential Conflicts of Interest

Greenhill is a wholly owned subsidiary of Mizuho Americas LLC, which, together with its subsidiaries and affiliates and other Mizuho Entities (collectively, "Mizuho"), acts as a full service investment bank engaged in securities trading activities as well as providing investment banking and financial advisory services, along with a diverse range of financial products and services to its customers and counterparties on a global basis. In the normal course of offering financial products and services to clients, Mizuho may act in several capacities (including, among others, issuer, market maker and/or liquidity provider, underwriter, distributor, index sponsor, swap counterparty and calculation agent) simultaneously with respect to a product or service which may give rise to potential conflicts of interest which may impact the performance of a product or service. Such interests may conflict with your interests or those of your clients and Recipient should be mindful of such potential conflicts of interest when reviewing this information. Mizuho may effect or have effected transactions for its own accounts in the financial instruments referred to in this publication or any related financial instruments or underlying assets. On the date of this publication, Mizuho or its affiliates and their respective officers, directors, employees, agents, representatives, advisors or controlling persons may have a long or short position in any of the financial instruments mentioned in this publication and may make a market or trade in financial instruments economically related to the financial instruments or underlying assets mentioned herein, in each case either as principal or as agent.

Any non-public information provided to Greenhill will be maintained in accordance with its internal policies and will be shared with other Greenhill and Mizuho affiliates on a need-to-know basis to the extent deemed necessary by the Greenhill to consider or consummate the transaction or provide service described in the Presentation. Additionally, Greenhill and its affiliates may use your confidential information to introduce and/or offer you or your affiliates new products and services. To the extent existing agreements prohibit such "cross selling", a Greenhill representative may seek your consent to share your confidential information with its affiliates if required by Japanese, U.S. or other applicable law. Please refer to further disclaimers on our website at: https://www.greenhill.com/en/legal